عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

KAUST Signs MoUs with Chinese Academic Institutions and Innovation Centers

A view of the King Abdullah University of Science and Technology (KAUST). (KAUST)
A view of the King Abdullah University of Science and Technology (KAUST). (KAUST)
TT
TT

KAUST Signs MoUs with Chinese Academic Institutions and Innovation Centers

A view of the King Abdullah University of Science and Technology (KAUST). (KAUST)
A view of the King Abdullah University of Science and Technology (KAUST). (KAUST)

The King Abdullah University of Science and Technology (KAUST) signed on Saturday various memorandums of understanding (MoUs) with prestigious academic institutions and leading global innovation centers in the Chinese city of Shenzhen.

The MoUs aim to boost collaboration in the fields of industrial innovation, technology transfer, research, talent exchange, training programs, and entrepreneurship.

The agreements were signed during a visit by a Chinese delegation, headed by Mayor of Shenzhen city Qin Weizhong, to the KAUST on Saturday.

The delegation included 50 representatives from various institutions, including Tsinghua University, Tsinghua Shenzhen International Graduate School (Tsinghua SIGS), Research Institute of Tsinghua University in Shenzhen (RITS), Chinese University of Hong Kong, Shenzhen (CUHK-Shenzhen), Shenzhen InnoX Academy, and Shenzhen Research Institute of Big Data (SRIBD).

Such partnerships represent a significant step in supporting the economic transformation efforts in Saudi Arabia, aiming to prepare a new generation of scientific research and innovation leaders while bolstering the higher education system in the Kingdom to unprecedented levels.

Partnerships with the Chinese city of Shenzhen are a pivotal component of KAUST’s new strategy, which was announced last month.

One of the strategy's goals is to solidify scientific collaboration between KAUST and renowned academic institutions and innovation centers worldwide. It also seeks to forge scientific alliances to promote the adoption of promising technologies and encourage research commercialization, thereby raising the Kingdom's economic competitiveness.

Shenzhen city is recognized as one of the world's foremost hubs for technological advancement and is the third-most economically and technologically advanced city in China, following Shanghai and Beijing.

It serves as a significant strategic partner in bolstering the innovation ecosystem in the Kingdom and further facilitates collaboration with leading companies, academics, and experts in the field of innovation in Shenzhen. This will in turn solidify KAUST’s reputation as a global hub for technology and innovation.

President of KAUST Dr. Tony Chan said the university's distinguished partnerships with prestigious institutions in Shenzhen will support KAUST's core objectives.

“These objectives include strengthening the promotion of its global research partnerships, nurturing exceptional talent, and delivering tangible benefits for the Kingdom,” he said.

Most Viewed

 
 
Varieties

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”